Tarsus Pharmaceuticals, Inc. (TARS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Tarsus Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Tarsus Pharmaceuticals, Inc. (TARS) has returned -14.33% so far this year and 36.56% over the past 12 months.

Based on dividend-adjusted daily data since Oct 16, 2020, TARS's average daily return is +0.17%, while the average monthly return is +3.39%. At this rate, your investment would double in approximately 1.7 years.

Historically, 53% of months were positive and 47% were negative. The best month was Dec 2020 with a return of +71.0%, while the worst month was May 2022 at -24.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.

On a daily basis, TARS closed higher 49% of trading days. The best single day was Dec 14, 2020 with a return of +20.1%, while the worst single day was Jul 25, 2023 at -24.8%.

Tarsus Pharmaceuticals, Inc. has an annualized alpha of 37.47%, beta of 0.89, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since October 19, 2020.

• This stock captured 123.52% of S&P 500 Index gains but only 71.59% of its losses — a favorable profile for investors.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TARS ranks 66 for risk / return — better than 66% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Tarsus Pharmaceuticals, Inc. (TARS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Tarsus Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Tarsus Pharmaceuticals, Inc. was 77.67%, occurring on May 6, 2022. Recovery took 643 trading sessions.

The current Tarsus Pharmaceuticals, Inc. drawdown is 14.98%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Tarsus Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Tarsus Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.